Advertisement
U.S. Markets closed
  • S&P Futures

    5,206.50
    -8.25 (-0.16%)
     
  • Dow Futures

    39,196.00
    -27.00 (-0.07%)
     
  • Nasdaq Futures

    18,172.50
    -59.00 (-0.32%)
     
  • Russell 2000 Futures

    2,047.20
    -2.60 (-0.13%)
     
  • Crude Oil

    82.56
    -0.16 (-0.19%)
     
  • Gold

    2,163.80
    -0.50 (-0.02%)
     
  • Silver

    25.30
    +0.03 (+0.14%)
     
  • EUR/USD

    1.0875
    -0.0001 (-0.0109%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2726
    -0.0003 (-0.0216%)
     
  • USD/JPY

    149.2030
    +0.1050 (+0.0704%)
     
  • BTC-USD

    65,936.20
    -1,741.43 (-2.57%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,455.19
    -285.25 (-0.72%)
     

How to Beat the Market with Biotech -- Bluebird bio, Halozyme Therapeutics, Merrimack Pharma, and Kite Pharma

NEW YORK, NY / ACCESSWIRE / February 11, 2016 / Last year biotech experienced a peak, essentially after the last five years of solid and consistent growth which nurtured several mergers and consolidations. The biotech ETF not surprisingly did well, stemming from M&A activity, innovation, and rising revenues from names such as Gilead and Amgen.

There is one secret Biotech stock that could be a billion dollar stock idea and its trading at a fraction of its asset value. The opportunity for investors is right now. This company could change the way therapeutics and drugs hit the market and revolutionize the way in which shareholders profit from it. Find out more at:

http://valuableinvestment.com/freealerts

ValuableInvestment.com trade alerts have been initiated on these stocks: bluebird bio Inc. (BLUE), Halozyme Therapeutics Inc. (HALO), Merrimack Pharmaceuticals Inc. (MACK), and Kite Pharma Inc. (KITE). Join us today and activate the free trade alerts and reports on these equities at:

http://valuableinvestment.com/freealerts

On Wednesday, February 10, 2016, the NASDAQ Composite ended the session at 4,283.59, up 0.35%, the Dow Jones Industrial Average edged 0.62% lower, to finish the day at 15,914.74, and the S&P 500 closed at 1,851.86, down 0.02%. Below is the selection of stocks we are following today on the Biotech front, see how they have performed at the last close:

bluebird bio Inc.'s stock edged 0.44% higher, to close the day at $45.99. The stock recorded a trading volume of 1.26 million shares, below its three months average volume of 1.56 million shares. bluebird bio Inc.'s shares have advanced 3.02% in the past one month, but the stock has plummeted 39.56% in the last three months. The company's shares are trading 19.22% below their 50-day moving average. Additionally, bluebird bio Inc. has a Relative Strength Index (RSI) of 46.19. Do not lose out on any BLUE's trade by activating your free access to the trade alerts now at:

http://valuableinvestment.com/BLUE

On Wednesday, shares in Halozyme Therapeutics Inc. recorded a trading volume of 1.48 million shares, close to their three months average volume of 1.44 million shares. The stock ended the day 1.51% lower at $7.17. The company is trading below its 50-day and 200-day moving averages by 47.09% and 58.10%, respectively. Furthermore, shares of Halozyme Therapeutics Inc. have an RSI of 20.29. Sign up for your trade alert on HALO at:

http://valuableinvestment.com/HALO

Merrimack Pharmaceuticals Inc.'s stock finished Wednesday's session 0.55% lower at $5.41. A total of 1.34 million shares were traded, which was below its three months average volume of 1.41 million shares. The company's shares are trading below their 50-day and 200-day moving averages by 25.84% and 44.43%, respectively. Merrimack Pharmaceuticals Inc.'s stock has an RSI of 34.54. Register for free on ValuableInvestment.com and activate your trade alert on MACK at:

http://valuableinvestment.com/MACK

On Wednesday, shares in Kite Pharma Inc. ended the session 1.64% higher at $40.99. The stock reported a trading volume of 0.91 million shares, below its three months average volume of 1.20 million shares. The company is trading 30.66% below its 50-day moving average and 34.08% below its 200-day moving average. Moreover, shares of Kite Pharma Inc. have an RSI of 32.29. Trade Alert on KITE is available for free at:

http://valuableinvestment.com/KITE

--

About ValuableInvestment.com:

Valuable Investment was founded in 2006 and has been successfully alerting investors and shareholders of the most profitable ways to earn a living on Wall Street. A decade is a very long time so we must be doing something right. We encourage everyone to come and try our strategy and see how we have been changing the foundation of research for years.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY

ValuableInvestment.com, the Author, the Reviewer, and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither valuableinvestment.com nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://valuableinvestment.com

RESTRICTIONS

ValuableInvestment.com is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press@valuableinvestment.com

SOURCE: ValuableInvestment.com

Advertisement